The Valley Desk

ArticleAdvances in therapyPublished

Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Advances in therapy
Published
Subject terms
Humans; Myasthenia Gravis; Receptors, Fc; Histocompatibility Antigens Class I; Treatment Outcome; Activities of Daily Living; Antibodies, Monoclonal, Humanized; Indirect Treatment Comparison; Generalized Myasthenia Gravis; Matching-adjusted Indirect Comparison; Rozanolixizumab; Efgartigimod
PubMed ID
41817915
PubMed Central ID
PMC13156109
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal